
Ardelyx (ARDX) Stock Forecast & Price Target
Ardelyx (ARDX) Analyst Ratings
Bulls say
Ardelyx Inc. reported a combined revenue increase of 18% year-over-year, totaling $483 million, with management projecting potential peak sales exceeding $1 billion by 2029. The company is actively pursuing growth for its IBSRELA product through ongoing Phase 3 trials for chronic idiopathic constipation, with topline data expected by 2027, while Xphozah's revenue guidance for fiscal year 2026 is set at $110 million to $120 million, bolstered by increasing prescribing patterns. Additionally, a significant 41% growth in the ex-Medicare Xphozah segment in 2025 reflects the effectiveness of Ardelyx's strategic investments in its sales and patient assistance initiatives, which are driving enhanced prescription volumes and patient engagement.
Bears say
Ardelyx Inc is facing significant financial challenges, as indicated by management's expectation of typical seasonal headwinds leading to an anticipated 18% quarter-over-quarter decline in Ibsrela sales for the first quarter of 2026, despite a projected full-year revenue of $422 million. The company's guidance for over $1 billion in peak net sales for Ibsrela appears overly optimistic and not yet reflected in market pricing, compounded by potential adverse effects of changes in reimbursement pricing structures and restrictions on product labeling that could hinder market traction. Additionally, Ardelyx reported a net loss of $0.4 million in the fourth quarter of 2025, alongside concerning adherence rates among patients, which further complicates the prospects for sustaining profitable growth.
This aggregate rating is based on analysts' research of Ardelyx and is not a guaranteed prediction by Public.com or investment advice.
Ardelyx (ARDX) Analyst Forecast & Price Prediction
Start investing in Ardelyx (ARDX)
Order type
Buy in
Order amount
Est. shares
0 shares